Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10969853 | 0.84 | LMNA (0.68) | TSHRCYP3A4LMNAKDM4EALDH1A1 | |
| SCHEMBL10498013 | 0.82 | TSHR (1.00) | TSHRCYP3A4LMNACA9KDM4E | |
| SCHEMBL14641571 | 0.81 | CYP3A4 (0.51) | TSHRCYP3A4LMNACA9KDM4E | |
| SCHEMBL3431542 | 0.80 | LMNA (0.69) | TSHRCYP3A4LMNAKDM4EALDH1A1 | |
| SCHEMBL3913432 | 0.77 | ALDH1A1 (0.57) | TSHRCYP3A4LMNAKDM4EALDH1A1 | |
| SCHEMBL18901650 | 0.77 | ALDH1A1 (0.67) | TSHRCYP3A4LMNAKDM4EALDH1A1 | |
| SCHEMBL5883468 | 0.75 | L3MBTL1 (0.56) | TSHRCYP3A4LMNAKDM4EALDH1A1 | |
| SCHEMBL16145545 | 0.75 | LMNA (0.53) | TSHRCYP3A4LMNAKDM4EALDH1A1 | |
| SCHEMBL5881830 | 0.74 | ALDH1A1 (0.65) | TSHRCYP3A4LMNAKDM4EALDH1A1 | |
| SCHEMBL7802436 | 0.74 | TSHR (0.76) | TSHRCYP3A4LMNACA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961202-B2 | Bis-benzimidazole compounds and methods of using the same | HNRNPH1, HNRNPH3, HNRNPUL2 | TSHR 3601/4885CYP3A4 4709/4885LMNA 963/4885 |
| US-20190152924-A1 | BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME | HNRNPH1, HNRNPH3, HNRNPUL2 | TSHR 3601/4885CYP3A4 4709/4885LMNA 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.